I-Mab Initial Public Offering and Nasdaq Listing
1/20/2020

Davis Polk advised the underwriters on the SEC-registered initial public offering by I-Mab of 7,407,400 American depositary shares, each 10 ADSs representing 23 ordinary shares, for total proceeds of $103.7 million. I-Mab has granted the underwriters an option to purchase up to an additional 1,111,110 ADSs. The ADSs are listed on the Nasdaq Global Market under the symbol “IMAB”.

I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab has developed an innovative pipeline of more than 10 clinical and pre-clinical stage assets through its internal research and development efforts and in-licensing arrangements with global pharmaceutical and biotech companies.

The Davis Polk corporate team included partners Li He and James C. Lin, counsel-registered foreign lawyer Xuelin (Steve) Wang and registered foreign lawyer Vera Xu. Counsel Alon Gurfinkel and associate Summer Xia provided tax advice. Partner David R. Bauer and associate Yifu Chen provided advice on intellectual property matters. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Hong Kong, London and New York offices.